title: New developments in epidemiology, diagnosis, and treatment of fascioliasis.
abstract: OBJECTIVE
  This review focuses on the recent developments in the epidemiology, burden of disease, diagnostic tests, and treatment of fascioliasis.
  
  
  RESULTS
  Recent epidemiologic data suggest that either the endemic areas are expanding or disease is being recognized in areas where it was not previously observed. In addition, recent data highlight the effects of fascioliasis on childhood anemia and nutrition. Diagnosis remains problematic, but newer diagnostic tests including antibody, antigen, and DNA detection tests may facilitate earlier diagnosis. Recent studies suggest that point-of-care testing may soon be possible. Treatment with triclabendazole is effective, but resistance is emerging in livestock and may pose a threat for patients.
  
  
  CONCLUSIONS
  Fascioliasis continues to emerge as an important neglected disease, with new studies highlighting the under-recognized burden of disease. Further studies are needed on burden of disease, improved diagnosis, and alternative to triclabendazole treatment.
authors: Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA. micabada@utmb.edu
authors: Miguel M
authors: MM
authors: Cabada
authors: A Clinton
authors: AC
authors: White
mesh_terms: D000871:Anthelmintics / Q000627:therapeutic use; D000909:Antibodies, Helminth / Q000032:analysis; D001562:Benzimidazoles / Q000627:therapeutic use; D017281:Cost of Illness; D004351:Drug Resistance; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005211:Fascioliasis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D019095:Point-of-Care Systems; D000077682:Triclabendazole
chemical_list: D000871:Anthelmintics; D000909:Antibodies, Helminth; D001562:Benzimidazoles; D000077682:Triclabendazole